> Business Sectors
> Biotechnology

Biotechnology

The Lithuanian biotechnology industry has been rapidly developing since the 1990s and is now regarded as one of the most sophisticated in Central and Eastern Europe. Companies within the sector employ approximately 700 people, including about 160 R&D experts, while its total annual revenues exceed EUR 50 million. The success of the Lithuanian biotechnology industry has been reinforced by the return of many Lithuanian scientists who have gained invaluable experience while working abroad.

There are over 18,000 R&D researchers and specialists working within the sector in Lithuania. Fifteen research institutions carry out chemical and biochemical research on protein, enzymes and nucleic acid for pharmaceutical purposes. Sixteen educational institutions, including five major universities, train high-caliber biotechnology and business specialists in cooperation with both domestic and foreign biotechnology companies. 

Industrial biotechnology

 

Lithuania has a highly developed agricultural and forestry sector which has grown significantly during the past decade, with particular success in the production of biofuel. It is expected that the sector's healthy growth will continue in coming years. Every year Lithuania produces a surplus of biomass that can be reproduced to biofuel:

  • Around 1 million tons of surplus grain
  • Over 4.5 million tons of residual biomass and waste products from stockbreeding
  • Over 2.5 million m3 of forestry residues are formed during wood products manufacturing

Key products of the Lithuanian life science industry

  • Fertilizers for agriculture
  • Paints for industries
  • DAP
  • PET production
  • Biopharma production

Key sector's competitive advantages

  • Wide spectrum of unique quality products
  • World-class researchers
  • Close cooperation between science and business
  • Exports are valued all over the world

Some of the leading sector's companies are Thermo Fisher Scientific, TEVA, SICOR Biotech, BIOK, Biocentras, Traidenis, etc. For success stories please click here.


TEVA  – Teva Pharmaceutical Industries (Israel) acquired in 2006 Sicor Biotech UAB, a leading Lithuanian enterprise of biotechnological pharmacy. The company produces recombinant proteins for medical use (interferon alpha-2b, human growth hormone, granulocyte colonies stimulating factor, erythropoietin). It is the only factory of its kind in Eastern and Central Europe. The company has a very well-equipped research centre in which experts develop technology for the production of recombinant proteins. An example of the company's success is the recently developed medicine for treating cancer that is as effective as the alternative drugs, but 25–35% less expensive.


Contact information

For questions or more information about the Lithuanian Biotechnology sector or for identifying suitable partner companies, please do not hesitate to contact:

Donata Mauricaitė
Project Manager

Enterprise Lithuania
A. Gostauto st. 40A
LT-01112
Vilnius, Lithuania
Tel: +370 (5) 264-9076
Email: d.mauricaite@enterpriselithuania.com